JPS Luncheon: Magid Abou-Gharbia, “Realities of Drug Discovery and Development in Today’s Environment”
Magid Abou-Gharbia. Image courtesy of Temple University School of Pharmacy.
The 2010–2011 season of the Joseph Priestley Society (JPS) lecture series began with the presentation, “Realities of Drug Discovery and Development in Today’s Environment,” by Magid Abou-Gharbia, associate dean for research, professor, and director, Center for Drug Discovery Research, Temple University, and retired senior vice president, Wyeth Pharmaceutical.
The pharmaceutical industry is facing enormous challenges, including tarnished image, declining efficiencies, patent expiration of key drugs, fierce price competition from generics, mergers and acquisitions, and high regulatory hurdles.
In order to face the current grim realities, pharmaceutical companies have adopted new strategies aimed at restoring public trust and confidence, addressing declining productivity, and cutting cost, while ensuring a steady stream of innovative therapeutics for patients.
About the Speaker
Magid Abou-Gharbia is associate dean for research, professor of medicinal chemistry, and director of the Moulder Center for Drug Discovery Research at the School of Pharmacy, Temple University.
Prior to joining Temple in 2008, Abou-Gharbia spent 26 years at Wyeth Pharmaceuticals, where he was senior vice president and head of chemical and screening sciences. In that role he was responsible for overseeing and directing Wyeth chemistry and the screening-research efforts of 500 scientists at four U.S. research facilities and 150 chemists in Hyderabad, India, in support of drug discovery.
Abou-Gharbia's group research efforts led to the discovery of five marketed drugs and many compounds currently under clinical evaluation.
Abou-Gharbia has a B.S. in pharmacy and pharmaceutical sciences and an M.S. in medicinal chemistry from the School of Pharmacy, Cairo University. He holds a Ph.D. from the University of Pennsylvania.
His scientific contributions include over 200 invited lectures, presentations, and publications. He is listed as inventor on 99 U.S. patents and over 350 patents worldwide.